EMA Authorised: Otulfi (ustekinumab) — Fresenius Kabi Deutschland GmbH

View source ↗

Summary

EMA authorised Otulfi, a ustekinumab product from Fresenius Kabi Deutschland GmbH, for Crohn's disease and Ulcerative colitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• OTULFI (USTEKINUMAB-AAUZ)

Snippet

Status: Authorised. Therapeutic area: Crohn Disease;Colitis, Ulcerative. MAH: Fresenius Kabi Deutschland GmbH. Decision date: 09/09/2025